CIK 0001745999 · Large accelerated filer
Beam Therapeutics Inc.
Sign in to watch- Ticker
- BEAM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 857-327-8775
- Business address
- 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139
- Former names
- Beam Therapeutics Inc.
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 4/A Derivatives Options or other derivatives
- 4 Planned sale CEO sold 11,654 shares at an average $29.63 ($345,334)
- 4 Planned sale President & CSO sold 3,672 shares at an average $29.73 ($109,164)
- 4 Planned sale Chief Legal Officer sold 2,092 shares at an average $29.63 ($61,996)
- 4 Planned sale Chief Medical Officer sold 16,099 shares at an average $29.87 ($480,843)
- 4 Planned sale Chief Financial Officer sold 4,640 shares at an average $29.74 ($137,978)
- 4 Option exercise Chief Legal Officer acquired 8,941 shares (option exercise)
- 4 Grant or award President & CSO acquired 20,000 shares (grant or award)
- 4 Option exercise CEO acquired 13,850 shares (option exercise)
- 4 Grant or award Chief Medical Officer acquired 20,000 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 20,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- SC 13G Stake Amended Statement of Ownership
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
- SC 13G/A Stake Amended Statement of Ownership
Page 15 of 26 · 514 filings